146 related articles for article (PubMed ID: 15448036)
1. Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Ahmad T; Eisen T
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6388S-92S. PubMed ID: 15448036
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
4. Renal-cell carcinoma--molecular pathways and therapies.
Brugarolas J
N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
[No Abstract] [Full Text] [Related]
5. New treatment approaches in metastatic renal cell carcinoma.
Mancuso A; Sternberg CN
Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
9. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
10. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
13. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
14. [New drugs; sunitinib and sorafenib].
van Bronswijk H; Dubois EA; Osanto S; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
16. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
[TBL] [Abstract][Full Text] [Related]
17. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
18. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
20. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
[Next] [New Search]